---
search:
  boost: 3
---

# Multiple Sclerosis

This is a subcategory of Central Nervous System (CNS) Agents.

## Decision Tree

- [CNS - Multiple Sclerosis - Non-Preferred - Bafiertam, Extavia, Fingolimod, Glatiramer, Glatopa, Kesimpta, Mavenclad, Mayzent, Plegridy, Ponvory, Teriflunomide, Vumerity, Zeposia](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUM0hNRjhWT0w5V0JYU1NVSTM4UVMwWTlXUyQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                                    | Generic Name | Quantity | Time (Days) |
|:---------------------------------------------|:-------------|:--------:|:-----------:|
| Avonex                                       |              |          |             |
| Betaseron                                    |              |          |             |
| Copaxone <sup>BvG ==(Process by NDC)==</sup> |              |          |             |
| Dalfampridine                                |              |          |             |
| Dimethyl Fumarate                            |              |          |             |
| Fingolimod                                   |              |          |             |
| Gilenya                                      |              |          |             |
| Kesimpta                                     |              |          |             |
| Rebif                                        |              |          |             |
| Teriflunomide                                |              |          |             |
 
### Non-Preferred

| Non-Preferred                                                                            | Generic Name | Quantity | Time (Days) |
|:-----------------------------------------------------------------------------------------|:-------------|:--------:|:-----------:|
| Bafiertam                                                                                |              |          |             |
| Extavia                                                                                  |              |          |             |
| <span title = "Brand Preferred: Copaxone">Glatiramer</span> <sup>Brand Preferred</sup>   |              |          |             |
| Glatopa                                                                                  |              |          |             |
| Mavenclad                                                                                |              |          |             |
| Mayzent                                                                                  |              |          |             |
| Plegridy                                                                                 |              |          |             |
| Ponvory                                                                                  |              |          |             |
| Tascenso ODT                                                                             |              |          |             |
| Vumerity                                                                                 |              |          |             |
| Zeposia                                                                                  |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

### Grandfathering*

Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug previously, but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^30 days^^ with at least ^^one preferred^^ drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Siponimod (Mayzent)

Additional Siponimod (Mayzent) Criteria

- Must provide documentation of genotype, liver function tests (LFTS) complete blood count (CBC), ophthalmic examination, varicella zoster virus antibodies, and electrocardiogram (ECG) 

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=36&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"} 

[Criteria](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#page=43){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20effective%2001.01.2024.pdf#page=17){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
